Biogen Inc.Biogen Inc.Biogen Inc.

Biogen Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪32.76 B‬USD
‪1.16 B‬USD
‪9.42 B‬USD
‪144.48 M‬
Beta (1Y)

About Biogen Inc.

Christopher A. Viehbacher
Employees (FY)
‪7.57 K‬
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Revenue to profit conversion
Debt level and coverage

See all ideas 

Summarizing what the indicators are suggesting.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BIIB is featured.

Frequently Asked Questions

The current price of BIIB is 228.33 USD — it has increased by 1.47% in the past 24 hours. Watch Biogen Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Biogen Inc. stocks are traded under the ticker BIIB.
BIIB stock has fallen by 0.66% compared to the previous week, the month change is a 1.08% fall, over the last year Biogen Inc. has showed a 17.98% decrease.
We've gathered analysts' opinions on Biogen Inc. future price: according to them, BIIB price has a max estimate of 350.00 USD and a min estimate of 200.00 USD. Watch BIIB chart and read a more detailed Biogen Inc. stock forecast: see what analysts think of Biogen Inc. and suggest that you do with its stocks.
BIIB reached its all-time high on Jun 7, 2021 with the price of 468.55 USD, and its all-time low was 0.33 USD and was reached on Dec 14, 1994. View more price dynamics on BIIB chart.
See other stocks reaching their highest and lowest prices.
BIIB stock is 3.80% volatile and has beta coefficient of 0.89. Track Biogen Inc. stock price on the chart and check out the list of the most volatile stocks — is Biogen Inc. there?
Today Biogen Inc. has the market capitalization of ‪32.76 B‬, it has increased by 3.15% over the last week.
Yes, you can track Biogen Inc. financials in yearly and quarterly reports right on TradingView.
Biogen Inc. is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
BIIB earnings for the last quarter are 3.67 USD per share, whereas the estimation was 3.47 USD resulting in a 5.78% surprise. The estimated earnings for the next quarter are 3.98 USD per share. See more details about Biogen Inc. earnings.
Biogen Inc. revenue for the last quarter amounts to ‪2.29 B‬ USD, despite the estimated figure of ‪2.31 B‬ USD. In the next quarter, revenue is expected to reach ‪2.38 B‬ USD.
BIIB net income for the last quarter is ‪393.40 M‬ USD, while the quarter before that showed ‪249.70 M‬ USD of net income which accounts for 57.55% change. Track more Biogen Inc. financial stats to get the full picture.
No, BIIB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 18, 2024, the company has ‪7.57 K‬ employees. See our rating of the largest employees — is Biogen Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Biogen Inc. EBITDA is ‪2.26 B‬ USD, and current EBITDA margin is 22.58%. See more stats in Biogen Inc. financial statements.
Like other stocks, BIIB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Biogen Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Biogen Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Biogen Inc. stock shows the sell signal. See more of Biogen Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.